A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effect of Intravenous BIIB023 (Anti-TWEAK) on Lower Limb Muscle Mass and Strength During and After Knee-Joint Immobilization in Healthy Male Volunteers
Phase of Trial: Phase I
Latest Information Update: 09 Jun 2015
Price : $35 *
At a glance
- Drugs BIIB 023 (Primary)
- Indications Muscular atrophy
- Focus Therapeutic Use
- Acronyms Anti-TWEAK
- Sponsors Biogen Idec
- 02 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Mar 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 01 Oct 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.